Abstracts tagged "drug toxicity and vasculitis"

Abstract Number: 1939 • 2016 ACR/ARHP Annual Meeting
Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Grant Hughes¹ and Meredith Barnes², ¹University of Washington, Seattle, WA, ²Medicine, University of Washington, Seattle, WA
Background/Purpose: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of…
Abstract Number: 208 • 2015 ACR/ARHP Annual Meeting
Neutrophil-Mediated Mechanisms of Drug-Induced Autoimmunity
Jorge Irizarry-Caro¹, Carmelo Carmona-Rivera¹, Elaine Novakovich¹, Venkataraman Subramaniam², Paul Thompson³, Mariana J. Kaplan⁴ and Peter C. Grayson⁵, ¹National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ³University of Massachusetts, Worcester, MA, ⁴Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Certain medications are known to induce autoimmune disease in humans, triggering clinical features and autoantibody profiles that mirror idiopathic systemic lupus erythematosus (SLE) and/or…
Abstract Number: 1085 • 2015 ACR/ARHP Annual Meeting
Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera², Meryl Waldman³, Karran Phillips⁴, Venkataraman Subramaniam⁵, Paul Thompson⁶, Jonathan D. Graf⁷ and Mariana J. Kaplan¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ³NIDDK, National Institutes of Health, Bethesda, MD, ⁴NIDA, National Institutes of Health, Baltimore, MD, ⁵Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ⁶Biochemistry and Molecular Pharmacology, University of Masshachussetts, Worcester, MA, ⁷Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Levamisole, an anti-helminth drug, has been implicated in cases of drug-induced autoimmunity in humans exposed to adulterated cocaine. Clinical manifestations of levamisole-induced autoimmunity include…
Abstract Number: 2776 • 2014 ACR/ARHP Annual Meeting
Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center
Montserrat Santos-Gómez¹, Francisco Ortiz Sanjuan¹, Ricardo Blanco¹, Jose L. Hernández², Vanesa Calvo-Río¹, Javier Loricera¹, Carmen Gonzalez-Vela³, Trinitario Pina Murcia⁴, Hector Fernandez-Llaca⁵, Susana Armesto⁵, Victor Martínez-Taboada¹, Javier Rueda-Gotor¹, Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ⁵Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose The 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides defined drug-associated immune complex vasculitis as a distinct entity included within the…
Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].